CIP2A Expression and Ovarian Cancer Survival
Author Information
Author(s): Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Bützow R, Ristimäki A
Primary Institution: Helsinki University Central Hospital and University of Helsinki
Hypothesis
The study investigates the role of CIP2A expression in serous ovarian cancer and its association with clinicopathological variables and survival outcomes.
Conclusion
CIP2A expression is associated with reduced survival and aggressive disease characteristics in ovarian cancer patients.
Supporting Evidence
- Strong cytoplasmic CIP2A positivity indicated a reduced ovarian cancer-specific 5-year survival of 31.6%.
- CIP2A expression was associated with high grade, advanced stage, and aneuploidy.
- Patients with weak CIP2A positivity had a 5-year survival of 42.4%.
Takeaway
CIP2A is a protein that can help doctors understand how aggressive a woman's ovarian cancer is; higher levels of it mean a worse chance of survival.
Methodology
The study involved retrospective analysis of tumor samples from 562 serous ovarian cancer patients, using immunohistochemistry to assess CIP2A expression and survival analysis through Kaplan–Meier method.
Potential Biases
Potential bias due to the retrospective nature of the study and reliance on historical patient records.
Limitations
The study is retrospective and may be affected by treatment heterogeneity among patients.
Participant Demographics
Median age at diagnosis was 60 years, with a range from 18 to 92 years.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 37.1–45.7
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website